Conference abstractPublished 2018
Selective LC-MS/MS method for simultaneous plasma determination of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and ibrutinib based on effective phospholipids removing clean-up method: application to therapeutic drug monitoring
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Liquid chromatography-tandem mass spectrometry (LCMS/MS) method has been developed and validated for simultaneous quantification of five tirosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) and one BrutonâÂ?Â?s tyrosine kinase inhibitor (ibrutinib) in human plasma. Stable isotope-labeled internal standards have been applied for each compound to minimize matrix effect which commonly occurs in MS analysis. The analytes and their internal standards were extracted from only 200 Ã?µL of human plasma using solid phase extraction (Versaplate-SCX). The compounds were eluted under gradient conditions using a Poroshell 120 ECC18 column (2.1 x 75 mm, 2.7 mm) at flow rate of 0.5 mL/ min and 60Ã?ºC. Analytical column was protected by a 0.2- Ã?¼m on-line filter. The mobile phase consisted of 0.1% formic acid in MilliQ water, pH=2 (solution A) and 0.1% formic acid in acetonitrile (solution B) (80:20; v/v). Total run time was nine minutes, including acquisition time of six minutes followed by a re-equilibration time of three minutes. 5 Ã?¼L of the sample was injected into the chromatographic system. All analytes were detected using the mode multiple reaction monitoring in the positive ionization mode. The method was validated according to the recommendations of regulatory agencies through tests of precision, accuracy, recovery, matrix effect, stability, sensitivity, and selectivity. Sample preparation method applied in the present assay removes more than 95% of main plasma phospholipids compared to protein precipitation. The method enables selective quantification of six compounds. Present assay is currently being applied to therapeutic drug monitoring of imatinib, dasatinib, nilotinib and ponatinib in clinical practice in order to individualize dose adjustment and manage adverse effect.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Drug Development and Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Aneta Wojnicz”
